BLAINJECTIONINJECTABLE
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
JOBEVNE (bevacizumab-nwgd) by Biocon is vascular endothelial growth factor-directed antibody interactions [moa]. First approved in 2025.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOBEVNE (bevacizumab-nwgd) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), approved April 2025 as a biosimilar to Avastin. It inhibits angiogenesis to restrict tumor blood supply across multiple solid tumor indications. This is Biocon's entry into the anti-VEGF biosimilar market.
Launch
New biosimilar entrant in a mature, competitive anti-VEGF market with moderate competitive pressure (30); launch-phase teams will focus on payer contracting and formulary placement.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JOBEVNE offers entry-level to mid-level pharma career opportunities in a launch-phase biosimilar product. Roles emphasize payer negotiations, formulary access, and competitive positioning rather than clinical development or deep medical expertise.
Brand ManagerManaged Care Specialist
Worked on JOBEVNE at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.